[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597292":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":11,"centralContacts":26,"locations":36,"responsibleParty":51,"collaborators":11,"id":55,"slug":11,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":11,"eligibilityCriteria":59,"healthyVolunteers":56,"sex":60,"minAge":61,"maxAge":11,"enrollmentInfo":62,"targetDuration":11,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":11,"overallStatus":38,"whyStopped":11,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Botkin Hospital","OTHER",[8,14,17],{"label":9,"type":10,"description":11,"interventionNames":12},"iRAS","EXPERIMENTAL",null,[13],"Drug: Finerenone",{"label":15,"type":10,"description":11,"interventionNames":16},"iSGLT2",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"iRAS+iSGLT2",[13],[21],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":11},"DRUG","Finerenone","Finerenone is a new nonsteroidal mineralocorticoid receptor antagonist. Planned dose - 10 mg\u002Fday",[9,18,15],[27,33],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"Evgeny Shytov, PhD","CONTACT","+7 499 490 03 03","5844","shutov_e_v@mail.ru",{"name":34,"role":29,"phone":11,"phoneExt":11,"email":35},"Anastasiia Zykova, PhD","ansezy@gmail.com",[37],{"facility":5,"status":38,"city":39,"state":11,"zip":11,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Moscow","Russia",{"type":42,"coordinates":43},"Point",[44,45],37.61781,55.75204,{"lat":45,"lon":44},[48],{"name":49,"role":29,"phone":50,"phoneExt":11,"email":35},"Anastasiia Zykova","89151345432",{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Evgeny Shutov","Senior Researcher","100597292",false,"NCT07056595","Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial","Inclusion Criteria:\n\n* Adults (\\> 18 years) with the primary IgAN diagnosed by kidney biopsy;\n* Treatment with stable doses of iRAS or\u002Fand iSGLT2 inhibitors for at least 3 months prior inclusion into the trial;\n* Blood pressure \\\u003C 140\u002F90 mm Hg\n* 24-hour urinary albumin excretion \\> 300 mg\n\nExclusion Criteria:\n\n* Kidney transplantation in medical history\n* Chronic hepatic disease, including hepatitis, malignant tumor, active malignancy;\n* Heart failure with ejection fraction \\\u003C40%;\n* Acute myocardial infarction and\u002For stroke less then 3 months before including in trial;\n* Presence ANCA in serum\n* Ongoing immunosuppressive treatment\n* eGFR \\\u003C 20 ml\u002Fmin\n* Pregnancy and breastfeeding\n* Uncontrolled blood pressure","ALL","18 Years",{"count":63,"type":64},30,"ESTIMATED","INTERVENTIONAL",[67],"NA",": IgA-nephropathy is the most common glomerulonephritis with the unfavorable prognosis in patients with persistent albuminuria. Finerenone is a new nonsteroidal mineralocorticoid receptor antagonist that has demonstrated efficacy in reducing albuminuria in patients with CKD and type 2 diabetes in two major trials, FIGARO-DKD and FIDELIO. This finding supported the approval of finerenone by the U.S. Food and Drug Administration (FDA) for the treatment of chronic kidney disease (CKD). A subgroup analysis in the pooled FIDELITY trial demonstrated that in patients with CKD stages 1-4 and type 2 diabetes (T2D), the cardio- and nephroprotective effects of finerenone were independent of concomitant therapy with SGLT-2 inhibitors or GLP-1 receptor agonists. Thus, the role of finerenone in slowing CKD progression in T2D can be considered well-established. Given its albuminuria-reducing effects, finerenone is being investigated in multiple trials, including studies on non-diabetic kidney disease and IgA nephropathy, though no published results are available yet. In this trial finerenone will be used as a nephroprotective agent above standard treatment in terms of assessing adverse events and potential efficacy.",[70],"IgA Nephropathy (IgAN)","2025-06-30",{"date":73,"type":74},"2025-07-09","ACTUAL",{"date":76,"type":74},"2025-05-21",{"date":78,"type":64},"2026-05-21",{"name":5,"class":6},1]